Argenx Shares Hit 52-Week High After Positive Vyvgart Hytrulo Trial Results
By Chris Wack
Argenx shares were up 30% to $492.01 Monday after the immunology company said it saw positive topline results from its study with biopharmaceutical company Zai Lab evaluating Vyvgart Hytrulo, or efgartigimod alfa and hyaluronidase-qvfc, in adults with chronic inflammatory demyelinating polyneuropathy.
Argenx stock hit its 52-week high of $498.63 earlier in the session and is up 35% over the past 12 months. Zai Lab shares were up 8% to $30.17.
The companies said the study met its primary endpoint, demonstrating a significantly lower risk of relapse with Vyvgart Hytrulo compared with placebo.
The study showed that the safety and tolerability profile was consistent with the confirmed safety profile of Vyvgart, and 91% of eligible patients continued to the next phase of the open-label extension study.
The most frequent treatment-related adverse event was injection site reactions, which occurred in a lower percentage of patients than previous Vyvgart Hytrulo trials. All injection site reactions were mild to moderate and resolved over time.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
July 17, 2023 10:49 ET (14:49 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
4 Utility Stocks to Play the AI Data Center Boom
-
Albemarle Earnings: We Expect Improved Results In the Rest of Year Following Cyclically Low Profits
-
Novo Nordisk Earnings: Raised Fair Value Estimate Still a Contrast to Market Overenthusiasm
-
After Earnings, Is Verizon Stock a Buy, a Sell, or Fairly Valued?
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
How to Invest Like Warren Buffett
-
Cognizant Earnings: Improved Profitability Buttresses Results as Customer Spending Remains Muted
-
10 Top-Performing Dividend Stocks of the Month